

Joong Bae Ahn

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/855053/joong-bae-ahn-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138
papers

2,586
citations

26
h-index

45
g-index

145
ext. papers

3,085
ext. citations

4.3
avg, IF

4.47
L-index

#	Paper	IF	Citations
138	Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. <i>Cancers</i> , 2022 , 14, 2659	6.6	2
137	74 Tumor microenvironment based on PD-L1 and CD8 T-cell infiltration correlated with the response of MSS mCRC patients treated vactosertib in combination with pembrolizumab 2021 , 9, A82-A82		0
136	823 Spatial analysis of tumor-infiltrating lymphocytes correlates with the response of metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab 2021 , 9, A861-A861		
135	Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. <i>Scientific Reports</i> , 2021 , 11, 20263	4.9	2
134	Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations. <i>Investigational New Drugs</i> , 2021 , 39, 1366-1374	4.3	2
133	A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2021 , 39, 1335-1347	4.3	0
132	Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3573-3573	2.2	2
131	Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations. <i>Cancer Research and Treatment</i> , 2021 ,	5.2	2
130	Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection. <i>World Allergy Organization Journal</i> , 2021 , 14, 100553	5.2	2
129	Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. <i>Cancer Science</i> , 2021 , 112, 4669-4678	6.9	4
128	A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. <i>Clinical Colorectal Cancer</i> , 2020 , 19, e140-e150	3.8	3
127	Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial. <i>European Journal of Cancer</i> , 2020 , 130, 51-62	7.5	13
126	Clinical Significance of Preoperative Serum Carcinoembryonic Antigen Within the Normal Range in Colorectal Cancer Patients Undergoing Curative Resection. <i>Annals of Surgical Oncology</i> , 2020 , 27, 2774-2783	3.1	6
125	Nomogram for prediction of pathologic complete remission using biomarker expression and endoscopic finding after preoperative chemoradiotherapy in rectal cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2020 , 32, 228-241	3.8	2
124	A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2020 , 52, 1135-1144	5.2	21
123	Clinical features and KRAS mutation in colorectal cancer with bone metastasis. <i>Scientific Reports</i> , 2020 , 10, 21180	4.9	6
122	The Role of Primary Tumor Resection in Colorectal Cancer Patients with Asymptomatic, Synchronous, Unresectable Metastasis: A Multicenter Randomized Controlled Trial. <i>Cancers</i> , 2020 , 12,	6.6	14

121	Objectively measured physical activity during chemotherapy in colon cancer patients. <i>Supportive Care in Cancer</i> , 2020 , 28, 2597-2604	3.9	1
120	Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. <i>Trials</i> , 2020 , 21, 320	2.8	4
119	Role of Preoperative Chemoradiotherapy in Clinical Stage II/III Rectal Cancer Patients Undergoing Total Mesorectal Excision: A Retrospective Propensity Score Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 609313	5.3	2
118	Treatment Outcomes of Re-irradiation in Locoregionally Recurrent Rectal Cancer and Clinical Significance of Proper Patient Selection. <i>Frontiers in Oncology</i> , 2019 , 9, 529	5.3	7
117	The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer. <i>Gastric Cancer</i> , 2019 , 22, 113-122	7.6	13
116	Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3111-3123	2.2	51
115	VEGF-A drives TOX-dependent T cell exhaustion in anti-PD-1-resistant microsatellite stable colorectal cancers. <i>Science Immunology</i> , 2019 , 4,	2.8	77
114	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. <i>Korean Journal of Internal Medicine</i> , 2019 , 34, 165-177	2.5	12
113	Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapelRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 711-711	2.2	
112	Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors. <i>Journal of Cancer Prevention</i> , 2019 , 24, 48-53	3	
111	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. <i>Clinical Cancer Research</i> , 2019 , 25, 1612-1623	12.9	76
110	A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 889-899	4	21
109	Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e513-e518	3.8	14
108	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 668-674	21.7	68
107	Mapping of lateral pelvic lymph node recurrences in rectal cancer: a radiation oncologist's perspective. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018 , 144, 1119-1128	4.9	3
106	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018 , 18, 158	4.8	12
105	T2-weighted signal intensity-selected volumetry for prediction of pathological complete response after preoperative chemoradiotherapy in locally advanced rectal cancer. <i>European Radiology</i> , 2018 , 28, 5231-5240	8	15
104	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	11

103	CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer. <i>Yonsei Medical Journal</i> , 2018 , 59, 588-594	3	18
102	Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. <i>Annals of Surgery</i> , 2017 , 265, 946-953	7.8	84
101	ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition. <i>Biochemical Pharmacology</i> , 2017 , 123, 73-84	6	2
100	A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 773-781	4.3	4
99	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. <i>BMC Cancer</i> , 2017 , 17, 615	4.8	8
98	Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer. <i>Oncology Letters</i> , 2017 , 14, 2385-2392	2.6	5
97	Reduced pelvic field sparing anastomosis for postoperative radiotherapy in selected patients with mid-upper rectal cancer. <i>Journal of Radiation Research</i> , 2017 , 58, 559-566	2.4	3
96	Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 227-235	3.1	28
95	High-risk clinicopathological features and their predictive significance in Korean patients with stage II colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016 , 142, 2051-9	4.9	9
94	The role of primary tumor resection in colorectal cancer patients with asymptomatic, synchronous unresectable metastasis: Study protocol for a randomized controlled trial. <i>Trials</i> , 2016 , 17, 34	2.8	26
93	Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2016 , 23, 928-35	3.1	22
92	A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. <i>Radiotherapy and Oncology</i> , 2016 , 118, 369-74	5.3	24
91	Patterns of recurrence by microsatellite instability in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 501-501	2.2	1
90	An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 642-642	2.2	1
89	Prognostic implications of PIK3CA amplification in curatively resected liposarcoma. <i>Oncotarget</i> , 2016 , 7, 24549-58	3.3	7
88	p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016 , 48, 208-15	5.2	9
87	Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study. <i>Cancer Research and Treatment</i> , 2016 , 48, 1420-1428	5.2	2
86	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial. <i>Cancer Research and Treatment</i> , 2016 , 48, 1210-1221	5.2	9

85	Review on history and current practices of cancer multidisciplinary care. <i>Journal of the Korean Medical Association</i> , 2016 , 59, 88	0.5	2
84	Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after neoadjuvant chemoradiation therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 760-760	2.2	
83	Association of ECOG performance status with efficacy in patients receiving panitumumab with best supportive care (BSC) vs BSC alone for chemorefractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15018-e15018	2.2	
82	MRI Risk Stratification for Tumor Relapse in Rectal Cancer Achieving Pathological Complete Remission after Neoadjuvant Chemoradiation Therapy and Curative Resection. <i>PLoS ONE</i> , 2016 , 11, e0146235	2.7	10
81	Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. <i>PLoS ONE</i> , 2016 , 11, e0161475	3.7	19
80	Study protocol of the Asian XELIRI Project (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. <i>Chinese Journal of Cancer</i> , 2016 , 35, 102		10
79	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016 , 16, 434	4.8	93
78	Biomarker-Based Scoring System for Prediction of Tumor Response After Preoperative Chemoradiotherapy in Rectal Cancer by Reverse Transcriptase Polymerase Chain Reaction Analysis. <i>Diseases of the Colon and Rectum</i> , 2016 , 59, 1174-1182	3.1	16
77	Circumferential resection margin positivity after preoperative chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer: implication of boost radiotherapy to the involved mesorectal fascia. <i>Japanese Journal of Clinical Oncology</i> , 2016 , 46, 316-22	2.8	3
76	Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. <i>British Journal of Cancer</i> , 2016 , 115, 25-33	8.7	87
75	Incorporation of radiotherapy in the multidisciplinary treatment of isolated retroperitoneal lymph node recurrence from colorectal cancer. <i>Annals of Surgical Oncology</i> , 2015 , 22, 1520-6	3.1	11
74	Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. <i>International Journal of Clinical Oncology</i> , 2015 , 20, 1226-32	4.2	7
73	A Randomized Phase 2 Study of Neoadjuvant Chemoradiation Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 1015-22	4	21
72	PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. <i>International Journal of Cancer</i> , 2015 , 136, 2273-83	7.5	9
71	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 2015 , 47, 9-17	5.2	7
70	Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 10565-10565	2.2	5
69	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , 2015 , 5, 72-86	4.4	10
68	Novel methods for clinical risk stratification in patients with colorectal liver metastases. <i>Cancer Research and Treatment</i> , 2015 , 47, 242-50	5.2	5

67	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015 , 47, 781-9	5.2	7
66	Predicting the pathologic response of locally advanced rectal cancer to neoadjuvant concurrent chemoradiation using enzyme-linked immunosorbent assays (ELISAs) for biomarkers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014 , 140, 399-409	4.9	4
65	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. <i>Lancet Oncology</i> , 2014 , 15, 1245-53	21.7	272
64	High KLF4 level in normal tissue predicts poor survival in colorectal cancer patients. <i>World Journal of Surgical Oncology</i> , 2014 , 12, 232	3.4	27
63	Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis. <i>Journal of Surgical Oncology</i> , 2014 , 110, 214-21	2.8	28
62	Vascular soft-tissue sarcomas: a prognostic model from a retrospective single-center study. <i>Oncology</i> , 2014 , 86, 329-35	3.6	
61	Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 74, 799-808	3.5	6
60	Differential expression of CD133 based on microsatellite instability status in human colorectal cancer. <i>Molecular Carcinogenesis</i> , 2014 , 53 Suppl 1, E1-10	5	10
59	Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?. <i>Diseases of the Colon and Rectum</i> , 2014 , 57, 592-601	3.1	37
58	MAPK-signaling inhibition as a genome-based precision medicine in refractory osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22164-e22164	2.2	
57	Assessment of efficiency and safety of the comprehensive Chemotherapy Assistance Program for ordering oncology medications. <i>International Journal of Medical Informatics</i> , 2013 , 82, 504-13	5.3	11
56	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013 , 21, 1751-9	3.9	27
55	Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study. <i>Annals of Surgical Oncology</i> , 2013 , 20, 3407-13	3.1	50
54	Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent. <i>Investigational New Drugs</i> , 2013 , 31, 1-13	4.3	10
53	Estimating the adjuvant chemotherapy effect in elderly stage II and III colon cancer patients in an observational study. <i>Journal of Surgical Oncology</i> , 2013 , 107, 613-8	2.8	17
52	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 853-60	3.5	5
51	Therapeutic strategies for well-differentiated papillary mesothelioma of the peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013 , 43, 996-1003	2.8	23
50	Changing treatment patterns in elderly patients with resectable colon cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2013 , 9, 265-72	1.9	8

49	A randomized phase II study of neoadjuvant chemoradiotherapy with 5-FU/leucovorin or irinotecan/S1 in patients with locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 511-511	2.2	1
48	Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience. <i>Radiation Oncology Journal</i> , 2013 , 31, 25-33	2.5	4
47	Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2012 , 69, 91-7	3.5	
46	A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 672-80	4.3	14
45	Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, e577-84	4	6
44	Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. <i>BMC Genomics</i> , 2012 , 13, 348	4.5	80
43	Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. <i>BMC Cancer</i> , 2012 , 12, 471	4.8	1
42	VIPoma that arose from the rectum in a 65-year-old male patient. <i>International Journal of Colorectal Disease</i> , 2012 , 27, 1385-6	3	2
41	Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. <i>Surgical Oncology</i> , 2012 , 21, e125-30	2.5	5
40	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. <i>Investigational New Drugs</i> , 2012 , 30, 1501-10	4.3	17
39	Prognostic significance of intermediate mucinous carcinoma in patients with microsatellite stable stage II or III colon cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3606-3606	2.2	
38	Mucinous histology to predict disease-free survival in microsatellite stable stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14084-e14084	2.2	14084
37	Genome-wide molecular characterization of mucinous colorectal adenocarcinoma using cDNA microarray analysis. <i>Oncology Reports</i> , 2011 , 25, 717-27	3.5	11
36	Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2011 , 29, 1073-80	4.3	6
35	Brain metastases from colorectal carcinoma: prognostic factors and outcome. <i>Journal of Neuro-Oncology</i> , 2011 , 101, 49-55	4.8	65
34	Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer. <i>Supportive Care in Cancer</i> , 2011 , 19, 971-8	3.9	20
33	Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. <i>Radiation Oncology</i> , 2011 , 6, 99	4.2	30
32	A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. <i>Cancer</i> , 2011 , 117, 2050-7	6.4	38

31	DNA methylation predicts recurrence from resected stage III proximal colon cancer. <i>Cancer</i> , 2011 , 117, 1847-54	6.4	126
30	Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis. <i>Oncology</i> , 2011 , 81, 175-83	3.6	16
29	Two dosages of oral fluoropyrimidine S-1 of 35 and 40 mg/m ² bid: comparison of the pharmacokinetic profiles in Korean patients with advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2010 , 40, 29-35	2.8	2
28	Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. <i>Cancer Letters</i> , 2010 , 288, 124-32	9.9	30
27	Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2010 , 95, 303-7	5.3	21
26	A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010 , 33, 56-60	2.7	2
25	Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?. <i>International Journal of Colorectal Disease</i> , 2010 , 25, 1103-10	3	17
24	A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. <i>Investigational New Drugs</i> , 2010 , 28, 650-8	4.3	15
23	The role of adjuvant pelvic radiotherapy in rectal cancer with synchronous liver metastasis: a retrospective study. <i>Radiation Oncology</i> , 2010 , 5, 75	4.2	21
22	Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. <i>Cancer Research and Treatment</i> , 2010 , 42, 217-24	5.2	20
21	Benefits of recurrent colonic stent insertion in a patient with advanced gastric cancer with carcinomatosis causing colonic obstruction. <i>Yonsei Medical Journal</i> , 2009 , 50, 296-9	3	2
20	Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 919-27	3.5	5
19	Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 64, 657-63	3.5	63
18	Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: abdominoperineal resection versus sphincter-preserving procedure. <i>Annals of Surgical Oncology</i> , 2009 , 16, 1266-73	3.1	32
17	G-T haplotype (2677G>T/A and 3435C>T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. <i>Cancer Letters</i> , 2009 , 277, 155-63	9.9	12
16	Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. <i>International Journal of Oncology</i> , 2009 , 34, 787-96	1	1
15	Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients. <i>BMC Cancer</i> , 2008 , 8, 8	4.8	11
14	Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer. <i>Cancer Letters</i> , 2008 , 270, 269-76	9.9	5

13	Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer. <i>Radiotherapy and Oncology</i> , 2008 , 87, 361-6	5.3	8
12	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 75-81	3.5	9
11	Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 61, 157-65	3.5	11
10	Robotic total mesorectal excision for rectal cancer using four robotic arms. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2008 , 22, 792-7	5.2	79
9	Standardization of the Korean version of Mini-Mental Adjustment to Cancer (K-Mini-MAC) scale: factor structure, reliability and validity. <i>Psycho-Oncology</i> , 2008 , 17, 592-7	3.9	45
8	S-1 monotherapy as a neoadjuvant treatment for locally advanced gastric cancer. <i>Korean Journal of Internal Medicine</i> , 2008 , 23, 37-41	2.5	
7	Curative Resection Following Neoadjuvant Chemotherapy Including a Molecularly Targeted Agent in Patients with Unresectable Colorectal Distant Metastases. <i>Journal of the Korean Society of Coloproctology</i> , 2008 , 24, 184		
6	Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy. <i>Acta Oncologica</i> , 2007 , 46, 547-9	3.2	0
5	Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. <i>Oncologist</i> , 2007 , 12, 543-54	5.7	31
4	A locally advanced breast cancer with difficult differential diagnosis of carcinosarcoma and atypical medullary carcinoma, which had poor response to adriamycin- and taxane-based neoadjuvant chemotherapy: a case report. <i>Cancer Research and Treatment</i> , 2007 , 39, 134-7	5.2	4
3	Long-term survival after surgical resection for liver metastasis from gastric cancer: two case reports. <i>Cancer Research and Treatment</i> , 2006 , 38, 184-8	5.2	1
2	Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005 , 62, 761-8	4	99
1	A pilot study of trans-arterial injection of 166Holmium-Chitosan complex for treatment of small hepatocellular carcinoma. <i>Yonsei Medical Journal</i> , 2005 , 46, 799-805	3	8